---
title: "US Equity Markets Mixed Amid Volatility, Crude Oil Price Rebound"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278613776.md"
description: "US equity markets showed mixed results amid volatility, with crude oil prices rebounding after earlier declines. Existing home sales rose 1.7% to an annual rate of 4.09 million units, surpassing expectations. Vertex Pharmaceuticals saw an 8.5% increase in shares following positive trial results for its kidney disease treatment. In contrast, Centene Corporation's shares fell 16% due to anticipated challenges in the Affordable Care Act marketplace, as noted by CEO Sarah London at a healthcare conference."
datetime: "2026-03-10T20:22:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278613776.md)
  - [en](https://longbridge.com/en/news/278613776.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278613776.md)
---

# US Equity Markets Mixed Amid Volatility, Crude Oil Price Rebound

04:22 PM EDT, 03/10/2026 (MT Newswires) -- US equity indexes were mixed Tuesday amid volatile trading after crude oil prices moved up after falling earlier in the day.

\* US existing home sales rose 1.7% sequentially to a seasonally adjusted annual rate of 4.09 million units last month, compared with an anticipated 0.8% decline, according to a Bloomberg-compiled survey.

\* April West Texas Intermediate crude oil fell $8.51 to settle at $86.26 per barrel, while May Brent crude, the global benchmark, was last seen up $7.92 at $91.02.

\* Vertex Pharmaceuticals ( VRTX ) said a prespecified week 36 interim analysis of its ongoing phase 3 trial of povetacicept in immunoglobulin A nephropathy, a kidney disease, showed favorable results. Shares of the company were up nearly 8.5%, the biggest gainer on the S&P 500 and Nasdaq.

\* Centene Corporation ( CNC ) shares were down roughly 16% after the company said it expects continuing headwinds in its operations in the Affordable Care Act marketplace, multiple media outlets reported, citing CEO Sarah London's presentation at the Barclays 28th Annual Global Healthcare Conference.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [CNC.US](https://longbridge.com/en/quote/CNC.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [12:33 ETBeach House Center for Recovery Announces In-Network Contract with Ambetter Health](https://longbridge.com/en/news/282228303.md)
- [08:00 ETLynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA](https://longbridge.com/en/news/282340368.md)
- [Stifel Nicolaus Reaffirms Their Buy Rating on Concurrent Technologies (CNC)](https://longbridge.com/en/news/282906491.md)
- [Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive](https://longbridge.com/en/news/282775123.md)
- [Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX](https://longbridge.com/en/news/282977301.md)